FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Allergy and Immunology Information Center
Allergists Affirm Safety of COVID-19 Vaccines for Most
Researchers provide reassurance regarding potential allergic reactions to mRNA COVID-19 vaccinations from Pfizer and Moderna.
Rapid Decay of IgA and IgM Following COVID-19 Infection
Study authors measured the levels of immunoglobulin M, IgG, and IgA in healthcare workers, and observed fast decay of 2 antibodies which has implications for further seroprevalence studies.
Top FDA Approvals of December 2020
In addition to 2 COVID-19 vaccines, the FDA approved multiple medications of import to nurse practitioners and physician assistants.
AAAAI/ACAAI/CSACI Consensus Statement on Infant Food Allergy Prevention
The AAAAI, ACAAI, and the CSACI have published a consensus statement and recommendations on nutritional interventions for the prevention of food allergy.
Pandemic-Related MMR Vaccine Decline Persists
There has been a 10% decline in young children receiving their first measles/mumps/rubella (MMR) vaccination by age 16 months.
ChAdOx1 nCoV-19 Vaccine Promising Against SARS-CoV-2 in Older Adults
AstraZeneca assessed the immunogenicity, safety, and efficacy of their novel chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1 nCoV-19.
Most US Adults Report That They Would Get COVID-19 Vaccine
Seventy-one percent of the US public report that they would get a COVID-19 vaccine, marking an increase from 63% in September.
High-Dose Trivalent Flu Shot No Better for Patients With CVD
For patients with high-risk CVD, high-dose trivalent inactivated influenza vaccination does not reduce cardiopulmonary hospitalization or all-cause mortality.
HPV Vaccine Generally Well Tolerated in Men
Human papillomavirus (HPV) vaccines are safe and well tolerated in male patients, with few reports of adverse events.
Flu Shot More Popular Than COVID-19 Vaccine Among Older Adults
Older adults are less likely to get a COVID-19 vaccine than a flu vaccine, according to the University of Michigan National Poll on Healthy Aging.
Standardizing Clinical Endpoints for COVID-19 Vaccine Efficacy Trials
To facilitate harmonized evaluation and comparison of the efficacy of COVID-19 vaccines, study authors proposed a general set of clinical endpoints, along with considerations to guide the selection of primary endpoints.
HIV+ Transplant Donors: Expanding Opportunities to Save HIV Patient Lives
The national organ shortage has led researchers to criticallyre-evaluate organ sources that previously were considered toorisky for HIV patients.
Influenza Vaccination Does Not Increase Risk for Guillain-Barré Syndrome
Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.
Concerns of Parents/Caregivers of Children With Food Allergy During COVID-19
The effect of coronavirus disease 2019 (COVID-19) on patients with food allergy and their parents and caregivers is substantial.
Interventions to Increase HPV Vaccine Coverage Cost-Effective
Three interventions for increased human papillomavirus vaccine coverage are cost-effective.
As Rollout Nears, Small Practices and Rural Clinics Anticipate Challenges Storing and Administering COVID-19 Vaccines
The much-awaited remedy to the widespread transmission of SARS-CoV-2 comes with many logistical caveats.
Vaccine Candidate AZD1222 Effective Against COVID-19
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
COVID-19 Vaccine Candidate More Than 90% Effective, Say Pfizer, BioNTech
The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Allergy and Immunology Information Center
